$-0.38 EPS Expected for GlycoMimetics (GLYC), Last Week Boohoo.Com PLC (LON:BOO) Coverage

July 17, 2017 - By Vivian Currie

Analysts expect GlycoMimetics Inc (NASDAQ:GLYC) to report $-0.38 EPS on August, 3.They anticipate $0.03 EPS change or 7.32% from last quarter’s $-0.41 EPS. After having $-0.34 EPS previously, GlycoMimetics Inc’s analysts see 11.76% EPS growth. About 207,350 shares traded. GlycoMimetics Inc (NASDAQ:GLYC) has risen 81.25% since July 17, 2016 and is uptrending. It has outperformed by 64.55% the S&P500.

Among 12 analysts covering Boohoo.com Plc (LON:BOO), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. Boohoo.com Plc had 94 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was downgraded by N+1 Singer to “Hold” on Thursday, December 15. The company was downgraded on Friday, January 8 by Panmure Gordon. The firm has “Buy” rating given on Wednesday, December 14 by Investec. The firm has “Buy” rating given on Tuesday, September 27 by N+1 Singer. The stock of Boohoo.Com PLC (LON:BOO) earned “Overweight” rating by Barclays Capital on Wednesday, April 27. The rating was upgraded by Beaufort Securities to “Buy” on Wednesday, September 30. N+1 Singer maintained the shares of BOO in report on Wednesday, August 26 with “Buy” rating. The company was maintained on Tuesday, September 27 by Peel Hunt. The stock has “Buy” rating by Beaufort Securities on Tuesday, January 3. Liberum Capital upgraded Boohoo.Com PLC (LON:BOO) rating on Thursday, June 8. Liberum Capital has “Buy” rating and GBX 300 target. See Boohoo.Com PLC (LON:BOO) latest ratings:

30/06/2017 Broker: Deutsche Bank Rating: Buy New Target: GBX 290.00 Initiates Starts
28/06/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
14/06/2017 Broker: Shore Capital Rating: Buy Maintain
14/06/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
13/06/2017 Broker: Citigroup Rating: Neutral New Target: GBX 270.00 Maintain
09/06/2017 Broker: Beaufort Securities Rating: Buy Maintain
08/06/2017 Broker: N+1 Singer Rating: Hold Maintain
08/06/2017 Broker: Barclays Capital Rating: Equal Weight New Target: GBX 220.00 Maintain
08/06/2017 Broker: Shore Capital Rating: Buy Maintain
08/06/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 185.00 New Target: GBX 300.00 Upgrade

Since May 19, 2017, it had 0 insider buys, and 2 selling transactions for $55,420 activity. $24,280 worth of GlycoMimetics Inc (NASDAQ:GLYC) was sold by Thackray Helen M. on Friday, May 19.

Among 4 analysts covering GlycoMimetics (NASDAQ:GLYC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GlycoMimetics had 7 analyst reports since August 10, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Friday, July 7 report. The rating was maintained by Stifel Nicolaus on Tuesday, June 6 with “Buy”. Cowen & Co maintained GlycoMimetics Inc (NASDAQ:GLYC) on Tuesday, June 6 with “Buy” rating. Jefferies maintained the shares of GLYC in report on Monday, June 5 with “Buy” rating. Cowen & Co initiated the shares of GLYC in report on Monday, August 15 with “Outperform” rating. The rating was upgraded by Zacks to “Hold” on Monday, August 10. The firm has “Buy” rating given on Tuesday, July 26 by SunTrust.

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The company has market cap of $332.35 million. The Firm focuses on the discovery and development of glycomimetic drugs. It currently has negative earnings. The Firm operates through the identification and development of glycomimetic compounds segment.

Investors sentiment increased to 1.79 in 2016 Q4. Its up 0.89, from 0.9 in 2016Q3. It improved, as 5 investors sold GlycoMimetics Inc shares while 9 reduced holdings. 9 funds opened positions while 16 raised stakes. 18.74 million shares or 2.76% more from 18.24 million shares in 2016Q3 were reported. Tower Research (Trc) has 486 shares for 0% of their portfolio. Jacobs Levy Equity Mngmt accumulated 19,200 shares or 0% of the stock. Geode Capital Management Ltd has invested 0% of its portfolio in GlycoMimetics Inc (NASDAQ:GLYC). First Personal Fin Serv stated it has 0% of its portfolio in GlycoMimetics Inc (NASDAQ:GLYC). Wall Street Associate invested 0.6% of its portfolio in GlycoMimetics Inc (NASDAQ:GLYC). National Bank Of Mellon invested in 35,820 shares. Moreover, Meeder Asset Inc has 0% invested in GlycoMimetics Inc (NASDAQ:GLYC). Ohio-based Strs Ohio has invested 0% in GlycoMimetics Inc (NASDAQ:GLYC). Manufacturers Life Insur The holds 159 shares. Morgan Stanley reported 35,076 shares stake. Vanguard Group reported 424,444 shares stake. 1,315 are owned by Legal General Group Public Limited Co. Blackrock Institutional Tru Co Na, a California-based fund reported 74,894 shares. Nea Com Ltd Llc owns 8.58M shares for 2.08% of their portfolio. Blackrock Invest Mngmt Limited Liability accumulated 0% or 38,085 shares.

The stock decreased 1.61% or GBX 3.64 on July 17, reaching GBX 222.49. About 2.55 million shares traded. Boohoo.Com PLC (LON:BOO) has 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: